About Abionic
Abionic is a company based in Epalinges (Switzerland) founded in 2010 by Iwan Märki and Nicolas Durand. Abionic has raised $28.94 million across 4 funding rounds from investors including Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz. Abionic offers products and services including abioSCOPE and PSP Assay. Abionic operates in a competitive market with competitors including OpGen, CytoVale, SphingoTec, Avails Medical and Qvella Corporation, among others.
- Headquarter Epalinges, Switzerland
- Founders Iwan Märki, Nicolas Durand
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.94 M (USD)
in 4 rounds
-
Latest Funding Round
$21.13 M (USD), Series C
Mar 28, 2018
-
Investors
Zurcher Kantonalbank
& 14 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abionic
Abionic offers a comprehensive portfolio of products and services, including abioSCOPE and PSP Assay.
Rapid tool for sepsis detection from blood samples in minutes.
Test to detect sepsis risk using Pancreatic Stone Protein.
People of Abionic
Unlock access to complete
Unlock access to complete
Funding Insights of Abionic
Abionic has successfully raised a total of $28.94M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abionic
Abionic has secured backing from 15 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on science and tech-driven startups
|
Locked | Locked | Locked | |
|
Investment in early-stage medical device and life science companies with network support.
|
Locked | Locked | Locked | |
|
Business Angels Switzerland is focused on investing in innovative startups.
|
Locked | Locked | Locked |
Investor details for Abionic
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abionic
Investment portfolio details for Abionic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Abionic
Detailed financials for Abionic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abionic Comparisons
Peer comparison for Abionic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abionic
Abionic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, CytoVale, SphingoTec, Avails Medical and Qvella Corporation, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Microfluidic-based biomarkers for the early detection of sepsis
|
|
| Locked | Locked | Locked |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed.
|
|
| Locked | Locked | Locked |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| Locked | Locked | Locked |
Develops innovative platforms for accurate and rapid bacteria diagnosis in healthcare.
|
Detailed competitors of Abionic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abionic
Complete news archive for Abionic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abionic
Abionic was founded in 2010.
Abionic is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.
Patrick Pestalozzi is the current CEO of Abionic.
Abionic is a funded company, having raised a total of $28.94M across 4 funding rounds to date.
Abionic was founded in 2010 and is based in Epalinges, Switzerland. Diagnostic tools for allergies are developed by the company within the healthcare sector. Operations focus on point-of-care solutions, including the abioSCOPE device for measuring IgE concentrations from blood samples, the abioGUIDE application for report viewing on mobile devices, and screening capsules that assess respiratory allergies using minimal blood volume.
Abionic's top competitors include CytoVale, Avails Medical and SphingoTec.
Abionic offers abioSCOPE and PSP Assay.
Abionic has 15 investors. Key investors include Zurcher Kantonalbank, Pierangelo Bottinelli, Philippe Glatz, Arkady Volozh, and Peter Brabeck-Letmathe.